Syndax Pharmaceuticals (SNDX) Receiving Somewhat Positive Media Coverage, Accern Reports

Press coverage about Syndax Pharmaceuticals (NASDAQ:SNDX) has been trending somewhat positive recently, according to Accern. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Syndax Pharmaceuticals earned a news sentiment score of 0.06 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.1191568265022 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Shares of Syndax Pharmaceuticals (NASDAQ SNDX) traded up $0.34 during mid-day trading on Friday, reaching $8.40. The company’s stock had a trading volume of 143,690 shares, compared to its average volume of 310,198. Syndax Pharmaceuticals has a 12-month low of $6.31 and a 12-month high of $15.70.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its earnings results on Tuesday, November 7th. The company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.12. The company had revenue of $0.31 million during the quarter, compared to the consensus estimate of $0.30 million. Syndax Pharmaceuticals had a negative return on equity of 57.90% and a negative net margin of 4,304.34%. The firm’s revenue for the quarter was up .0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.84) earnings per share. equities research analysts forecast that Syndax Pharmaceuticals will post -3.03 EPS for the current fiscal year.

Several analysts have weighed in on SNDX shares. Oppenheimer boosted their price objective on Syndax Pharmaceuticals to $29.00 and gave the company an “outperform” rating in a research report on Friday, August 11th. Nomura lowered their price objective on Syndax Pharmaceuticals from $27.00 to $22.00 and set a “buy” rating for the company in a research report on Friday, August 11th. Citigroup set a $20.00 price objective on Syndax Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 11th. Instinet reiterated a “buy” rating and issued a $22.00 price objective (down previously from $27.00) on shares of Syndax Pharmaceuticals in a research report on Monday, August 14th. Finally, Zacks Investment Research downgraded Syndax Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 17th. Two investment analysts have rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $23.13.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.

Insider Buying and Selling by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals Inc and related companies with's FREE daily email newsletter.

Leave a Reply